We are a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. We use our proprietary technology to create novel small molecule drug conjugates, or SMDCs. We are also developing companion imaging agents for each of our SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. This combination of an SMDC with its companion imaging agent is designed to personalize the treatment of patients by delivering effective therapy, selectively to diseased cells, in patients most likely to benefit. Our lead SMDC, Vynfinit® (Vintafolid Vitamin B desacetylvinblastine monohydrazide conjugate) delivers a potent vinca alkaloid chemotherapy directly to cancer cells by targeting the folate receptor. Patients most likely to respond to Vynfinit® are selected by using a non-invasive companion imaging agent Folcepri® (99mTc-etarfolatide) scan. Vynfinit® is currently being tested in the Phase 2b randomized TARGET clinical trial on pre-treated NSCLC. EC1456 is our second folate targeted SMDC which carries a more potent drug payload, tubulysin. This agent is currently in a phase 1 dose escalation study. We are developing other SMDCs to target other receptors which may allow for the expansion of this approach to additional cancers and inflammatory diseases.